IBDEI2AX ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,38658,1,3,0)
 ;;=3^Traumatic spondylopathy, lumbosacral region
 ;;^UTILITY(U,$J,358.3,38658,1,4,0)
 ;;=4^M48.37
 ;;^UTILITY(U,$J,358.3,38658,2)
 ;;=^5012121
 ;;^UTILITY(U,$J,358.3,38659,0)
 ;;=M48.31^^180^1980^59
 ;;^UTILITY(U,$J,358.3,38659,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38659,1,3,0)
 ;;=3^Traumatic spondylopathy, occipito-atlanto-axial region
 ;;^UTILITY(U,$J,358.3,38659,1,4,0)
 ;;=4^M48.31
 ;;^UTILITY(U,$J,358.3,38659,2)
 ;;=^5012115
 ;;^UTILITY(U,$J,358.3,38660,0)
 ;;=M48.38^^180^1980^60
 ;;^UTILITY(U,$J,358.3,38660,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38660,1,3,0)
 ;;=3^Traumatic spondylopathy, sacral and sacrococcygeal region
 ;;^UTILITY(U,$J,358.3,38660,1,4,0)
 ;;=4^M48.38
 ;;^UTILITY(U,$J,358.3,38660,2)
 ;;=^5012122
 ;;^UTILITY(U,$J,358.3,38661,0)
 ;;=M48.35^^180^1980^62
 ;;^UTILITY(U,$J,358.3,38661,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38661,1,3,0)
 ;;=3^Traumatic spondylopathy, thoracolumbar region
 ;;^UTILITY(U,$J,358.3,38661,1,4,0)
 ;;=4^M48.35
 ;;^UTILITY(U,$J,358.3,38661,2)
 ;;=^5012119
 ;;^UTILITY(U,$J,358.3,38662,0)
 ;;=M48.33^^180^1980^56
 ;;^UTILITY(U,$J,358.3,38662,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38662,1,3,0)
 ;;=3^Traumatic spondylopathy, cervicothoracic region
 ;;^UTILITY(U,$J,358.3,38662,1,4,0)
 ;;=4^M48.33
 ;;^UTILITY(U,$J,358.3,38662,2)
 ;;=^5012117
 ;;^UTILITY(U,$J,358.3,38663,0)
 ;;=M48.34^^180^1980^61
 ;;^UTILITY(U,$J,358.3,38663,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38663,1,3,0)
 ;;=3^Traumatic spondylopathy, thoracic region
 ;;^UTILITY(U,$J,358.3,38663,1,4,0)
 ;;=4^M48.34
 ;;^UTILITY(U,$J,358.3,38663,2)
 ;;=^5012118
 ;;^UTILITY(U,$J,358.3,38664,0)
 ;;=R47.01^^180^1981^1
 ;;^UTILITY(U,$J,358.3,38664,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38664,1,3,0)
 ;;=3^Aphasia
 ;;^UTILITY(U,$J,358.3,38664,1,4,0)
 ;;=4^R47.01
 ;;^UTILITY(U,$J,358.3,38664,2)
 ;;=^5019488
 ;;^UTILITY(U,$J,358.3,38665,0)
 ;;=I69.920^^180^1981^2
 ;;^UTILITY(U,$J,358.3,38665,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38665,1,3,0)
 ;;=3^Aphasia following unspecified cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,38665,1,4,0)
 ;;=4^I69.920
 ;;^UTILITY(U,$J,358.3,38665,2)
 ;;=^5007553
 ;;^UTILITY(U,$J,358.3,38666,0)
 ;;=I69.91^^180^1981^3
 ;;^UTILITY(U,$J,358.3,38666,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38666,1,3,0)
 ;;=3^Cognitive deficits following unsp cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,38666,1,4,0)
 ;;=4^I69.91
 ;;^UTILITY(U,$J,358.3,38666,2)
 ;;=^5007552
 ;;^UTILITY(U,$J,358.3,38667,0)
 ;;=I69.991^^180^1981^5
 ;;^UTILITY(U,$J,358.3,38667,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38667,1,3,0)
 ;;=3^Dysphagia following unspecified cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,38667,1,4,0)
 ;;=4^I69.991
 ;;^UTILITY(U,$J,358.3,38667,2)
 ;;=^5007569
 ;;^UTILITY(U,$J,358.3,38668,0)
 ;;=G11.1^^180^1981^6
 ;;^UTILITY(U,$J,358.3,38668,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38668,1,3,0)
 ;;=3^Early-onset cerebellar ataxia
 ;;^UTILITY(U,$J,358.3,38668,1,4,0)
 ;;=4^G11.1
 ;;^UTILITY(U,$J,358.3,38668,2)
 ;;=^5003753
 ;;^UTILITY(U,$J,358.3,38669,0)
 ;;=I69.952^^180^1981^11
 ;;^UTILITY(U,$J,358.3,38669,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38669,1,3,0)
 ;;=3^Hemiplga fol unsp cerebvasc disease aff left dominant side
 ;;^UTILITY(U,$J,358.3,38669,1,4,0)
 ;;=4^I69.952
 ;;^UTILITY(U,$J,358.3,38669,2)
 ;;=^5133586
 ;;^UTILITY(U,$J,358.3,38670,0)
 ;;=I69.954^^180^1981^12
 ;;^UTILITY(U,$J,358.3,38670,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38670,1,3,0)
 ;;=3^Hemiplga fol unsp cerebvasc disease aff left nondom side
